Incyte Co. (NASDAQ:INCY) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 8,241,237 shares, an increase of 18.2% from the November 30th total of 6,971,562 shares. Currently, 3.9% of the shares of the company are sold short. Based on an average trading volume of 1,559,472 shares, the short-interest ratio is currently 5.3 days.
In other Incyte news, insider David W. Gryska sold 6,760 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $98.87, for a total value of $668,361.20. Following the sale, the insider now directly owns 20,752 shares of the company’s stock, valued at $2,051,750.24. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider David W. Gryska sold 3,915 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $105.63, for a total transaction of $413,541.45. The disclosure for this sale can be found here. Over the last three months, insiders sold 44,878 shares of company stock worth $4,636,494. 17.70% of the stock is owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in INCY. Gamco Investors INC. ET AL acquired a new stake in Incyte in the 2nd quarter valued at about $327,000. Blair William & Co. IL acquired a new stake in Incyte in the 2nd quarter valued at about $582,000. Bronfman E.L. Rothschild L.P. raised its holdings in Incyte by 41.5% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,343 shares of the biopharmaceutical company’s stock valued at $421,000 after acquiring an additional 980 shares during the last quarter. Eagle Asset Management Inc. acquired a new stake in Incyte in the 2nd quarter valued at about $26,423,000. Finally, Swiss National Bank raised its holdings in Incyte by 3.7% in the 2nd quarter. Swiss National Bank now owns 623,000 shares of the biopharmaceutical company’s stock valued at $78,442,000 after acquiring an additional 22,200 shares during the last quarter. Institutional investors own 90.74% of the company’s stock.
Shares of Incyte (NASDAQ:INCY) opened at $96.62 on Thursday. The company has a market cap of $20,390.00, a PE ratio of -120.78 and a beta of 0.74. The company has a quick ratio of 4.81, a current ratio of 4.82 and a debt-to-equity ratio of 0.01. Incyte has a 1-year low of $92.91 and a 1-year high of $153.15.
Incyte (NASDAQ:INCY) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.17 EPS for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.11. The company had revenue of $381.50 million during the quarter, compared to the consensus estimate of $360.34 million. Incyte had a negative net margin of 10.90% and a negative return on equity of 12.91%. Incyte’s quarterly revenue was up 41.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.19 EPS. equities research analysts expect that Incyte will post -1.32 earnings per share for the current year.
Several equities research analysts have commented on the stock. BMO Capital Markets reaffirmed a “buy” rating and issued a $172.00 price target on shares of Incyte in a report on Wednesday, January 3rd. Royal Bank of Canada raised shares of Incyte from a “sector perform” rating to an “outperform” rating and set a $136.00 price target on the stock in a report on Tuesday, January 2nd. Oppenheimer set a $120.00 price target on shares of Incyte and gave the company a “hold” rating in a report on Tuesday, January 2nd. Citigroup reissued a “market perform” rating and set a $120.00 target price (down from $135.00) on shares of Incyte in a research note on Tuesday, January 2nd. Finally, Goldman Sachs Group initiated coverage on shares of Incyte in a research note on Friday, October 6th. They set a “buy” rating and a $160.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $143.11.
TRADEMARK VIOLATION WARNING: This news story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/11/short-interest-in-incyte-co-incy-increases-by-18-2.html.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.